Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Precision oncology using ex vivo technology: a step towards individualised cancer care?
Sophie Williams, Greg Wells, Samantha Conroy, et al.
Expert Reviews in Molecular Medicine (2022) Vol. 24
Open Access | Times Cited: 19

Showing 19 citing articles:

Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
Cambridge Prisms Precision Medicine (2024) Vol. 2
Open Access | Times Cited: 8
Facilitation of Tumor Stroma-Targeted Therapy: Model Difficulty and Co-Culture Organoid Method
Qiushi Feng, Xiaofeng Shan, Vicky Yau, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 62-62
Open Access | Times Cited: 1
Ex Vivo Drug Screening: An Emerging Paradigm in the Treatment of Childhood Cancer
Anees Ahmed, Emily R. Cox, Lindsay Lane, et al.
Journal of Pediatric Hematology/Oncology (2025)
Closed Access
Lung cancer: Current status of preclinical research
Emmanuel Boadi Amoafo, Elizabeth Twum, Bismarck Afedo Hottor, et al.
Elsevier eBooks (2025), pp. 95-114
Closed Access
Standardized assays to monitor drug sensitivity in hematologic cancers
Pilar Ayuda‐Durán, Johanne U. Hermansen, Mariaserena Giliberto, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Ex vivo therapeutic screening of metastatic cSCC: A review of methodological considerations for clinical implementation
Jessica Conley, Jay R. Perry, Bruce Ashford, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 4
Open Access | Times Cited: 2
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients
Hannah Gagg, Sophie Williams, Samantha Conroy, et al.
F1000Research (2023) Vol. 12, pp. 954-954
Open Access | Times Cited: 6
Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms
Biswanath Majumder, Nishanth Belugali Nataraj, Leela Maitreyi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Ex-vivo models of post-surgical residual disease in human glioblastoma
Ola Rominiyi, Connor McGarrity-Cottrell, Katie Myers, et al.
F1000Research (2024) Vol. 13, pp. 1316-1316
Open Access | Times Cited: 1
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients
Hannah Gagg, Sophie Williams, Samantha Conroy, et al.
F1000Research (2024) Vol. 12, pp. 954-954
Open Access
Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR4
Bass Hassan
(2024)
Open Access
Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR6
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR2
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Recommendation: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R1/PR5
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Decision: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR3
Nesrine Lajmi, Sofia Alves-Vasconcelos, Apostolos Tsiachristas, et al.
(2024)
Open Access
Immunophenotyping with (phospho)protein profiling and fluorescent cell barcoding for single-cell signaling analysis and biomarker discovery
Johanne U. Hermansen, Yanping Yin, Idun Dale Rein, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access
Potential of ex vivo organotypic slice cultures in neuro-oncology
Ariane Steindl, Manuel Valiente
Neuro-Oncology (2024)
Closed Access
Experimental Modeling and Treatment Strategies for Peritoneal Carcinomatosis
Aras Emre Canda, Tolga Sever
Turkish Journal of Colorectal Disease (2024) Vol. 34, Iss. 4, pp. 109-122
Open Access
Author comment: Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm — R0/PR1
Bass Hassan
(2023)
Open Access
Page 1

Scroll to top